Analysis of factors contributing to higher erythropoietin levels in patients with chronic liver disease

References

• Orrego H, Israel Y, Blake JE, Medline A. Assessment of prognostic factors in alcoholic liver disease: toward a global quantitative expression of severity. Hepatology 1983;3:896–905.
   PubMed Web of Science ®Google Scholar
• Christensen E, Schlichting P, Andersen PK, Fauerholdt L, Schou G, Pedersen BV, et al. Updating prognosis and therapeutic effect evaluation in cirrhosis with Cox’s multiple regression model for time-dependent variables. Scand J Gastroenterol 1986;21:163–74.
   PubMed Web of Science ®Google Scholar
• Means RT Jr, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992;80:1639–47.
   PubMedGoogle Scholar
• Sheehy TW, Berman A. The anaemia of cirrhosis. J Lab Clin Med 1960;56:72–82.
   PubMedGoogle Scholar
• Siciliano M, Tomasello D, Milani A, Ricerca BM, Storti S, Rossi L. Reduced serum levels of immunoreactive erythropoietin in patients with cirrhosis and chronic anemia. Hepatology 1995;22: 1132–35.
   PubMed Web of Science ®Google Scholar
• Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood). 2003;228:1–14.
   PubMed Web of Science ®Google Scholar
• Sasaki R. Pleiotropic functions of erythropoietin. Intern Med 2003;42:142–9.
   PubMed Web of Science ®Google Scholar
• Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 2003;100:4802–6.
   PubMed Web of Science ®Google Scholar
• Bahlmann FH, De Groot K, Spandau JM, Landry AL, Hertel B, Duckert T, et al. Erythropoietin regulates endothelial progenitor cells. Blood 2003. In press.
   Google Scholar
• Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003;112:999–1007.
   PubMed Web of Science ®Google Scholar
• Moon C, Krawczyk M, Ahn D, Ahmet I, Paik D, Lakatta EG, et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci USA. 2003;100:11612–7.
   PubMed Web of Science ®Google Scholar
• Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnotto A, et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 2003;198:971–5.
   PubMed Web of Science ®Google Scholar
• Yang CW, Li C, Jung JY, Shin SJ, Choi BS, Lim SW, et al. Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J 2003; 17: 1754–5.
   PubMed Web of Science ®Google Scholar
• Ebert BL, Bunn HF. Regulation of the erythropoietin gene. Blood 1999;94:1864–77.
   PubMed Web of Science ®Google Scholar
• Pirisi M, Fabris C, Falleti E, Soardo G, Toniutto P, Gonano F, et al. Evidence for a multifactorial control of serum erythropoietin concentration in liver disease. Clin Chim Acta 1993;219:47–55.
   PubMed Web of Science ®Google Scholar
• Vasilopoulos S, Hally R, Caro J, Martin P, Westerberg S, Moritz M, et al. Erythropoietin response to post-liver transplantation anemia. Liver Transpl 2000;6:349–55.
   PubMed Web of Science ®Google Scholar
• Mady E, Wissa G, Khalifa A, El-Sabbagh M. Assessment of erythropoietin levels and some iron indices in chronic renal failure and liver cirrhosis patients. Dis Markers 1999;15:229–36.
   Google Scholar
• Yang YY, Lin HC, Lee WC, Huang YT, Hou MC, Lee FY, et al. Plasma erythropoietin level in patients with cirrhosis and its relationship to the severity of cirrhosis and renal function. J Gastroenterol Hepatol 2003;18:1156–61.
   PubMed Web of Science ®Google Scholar
• Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res 1998;18:555–9.
   PubMed Web of Science ®Google Scholar
• Tilg H, Wilmer A, Vogel W, Herold M, Nolchen B, Judmaier G, et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992;103:264–74.
   PubMed Web of Science ®Google Scholar
• Spivak JL, Hogans BB. The in vivo metabolism of recombinant human erythropoietin in the rat. Blood 1989;73:90–9.
   PubMed Web of Science ®Google Scholar
• Tacke F, Schoffski P, Trautwein C, Luedde T, Ganser A, Manns MP, et al. Plasma P-selectin levels are elevated in patients with chronic liver disease. Blood Coagul Fibrinol 2003;14:319–25.
   PubMedGoogle Scholar
• Tacke F, Schöffski P, Trautwein C, Martin MU, Stangel W, Seifried E, et al. Endogenous serum levels of thrombopoietic cytokines in healthy whole-blood and platelet donors: implications for plateletpheresis. Br J Haematol 1999;105:511–3.
   PubMedGoogle Scholar
• Tacke F, Brabant G, Kruck E, Horn R, Schöffski P, Hecker H, et al. Ghrelin in chronic liver disease. J Hepatol 2003;38:447–54.
   Google Scholar
• Quandt K, Frech K, Karas H, Wingender E, Werner T. MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res 1995;23:4878–84.
   Google Scholar
• Glockner G, Scherer S, Schattevoy R, Boright A, Weber J, Tsui LC, et al. Large-scale sequencing of two regions in human chromosome 7q22: analysis of 650 kb of genomic sequence around the EPO and CUTL1 loci reveals 17 genes. Genome Res 1998;8:1060–73.
   PubMedGoogle Scholar
• Streetz KL, Tacke F, Leifeld L, Wustefeld T, Graw A, Klein C, et al. Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases. Hepatology 2003;38:218–29.
   PubMed Web of Science ®Google Scholar
• Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M, Kreil A, Hofer H, Jessner W, et al. Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. Gastroenterology 2002;123:141–51.
   Google Scholar
• Mangoni ED, Marrone A, Saviano D, Del Vecchio C, Utili R, Ruggiero G. Normal erythropoietin response in chronic hepatitis C patients with ribavirin-induced anaemia. Antivir Ther 2003;8: 57–63.
   Google Scholar
• Jensen JD, Jensen LW, Madsen JK, Poulsen L. The metabolism of erythropoietin in liver cirrhosis patients compared with healthy volunteers. Eur J Haematol 1995;54:111–6.
   PubMed Web of Science ®Google Scholar
• Berridge MV, Fraser JK, Carter JM, Lin FK. Effects of recombinant human erythropoietin on megakaryocytes and on platelet production in the rat. Blood 1988;72:970–7.
   PubMed Web of Science ®Google Scholar
• Ishibashi T, Koziol JA, Burstein SA. Human recombinant erythropoietin promotes differentiation of murine megakaryocytes in vitro. J Clin Invest 1987;79:286–9.
   PubMed Web of Science ®Google Scholar
• Winearls CG. Recombinant human erythropoietin: 10 years of clinical experience. Nephrol Dial Transplant 1998; 13 Suppl 2: 3–8.
   PubMedGoogle Scholar
• Wolber EM, Jelkmann W. Thrombopoietin: the novel hepatic hormone. News Physiol Sci 2002;17:6–10.
   PubMedGoogle Scholar
• Tacke F, Trautwein C, Zhao S, Andreeff M, Manns MP, Ganser A, et al. Quantification of hepatic thrombopoietin mRNA transcripts in patients with chronic liver diseases shows maintained gene expression in different etiologies of liver cirrhosis. Liver 2002;22:205–12.
   PubMedGoogle Scholar
• Pirisi M, Fabris C, Soardo G, Cecchin E, Toniutto P, Bartoli E. Thrombocytopenia of chronic liver disease corrected by erythropoietin treatment. J Hepatol 1994;21:376–80.
   PubMedGoogle Scholar
• Williams EJ, Iredale JP. Liver cirrhosis. Postgrad Med J 1998;74: 193–202.
   PubMed Web of Science ®Google Scholar
• Oczko-Grzesik B, Wiecek A, Kokot F. Influence of IFN-alpha on plasma erythropoietin levels in patients with hepatitis B virus-associated chronic active hepatitis. J Interferon Cytokine Res 2001;21:669–76.
   Google Scholar
• Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1992;79:1987–94.
   Google Scholar
• Jelkmann WE, Fandrey J, Frede S, Pagel H. Inhibition of erythropoietin production by cytokines. Implications for the anemia involved in inflammatory states. Ann NY Acad Sci 1994; 718:300–9.
   PubMed Web of Science ®Google Scholar
• Huang LE, Bunn HF. Regulation of erythropoietin gene expression. Curr Opin Hematol 1995;2:125–31.
   PubMedGoogle Scholar
• Imagawa S, Izumi T, Miura Y. Positive and negative regulation of the erythropoietin gene. J Biol Chem 1994;269:9038–44.
   Google Scholar
• Heinrich PC, Behrmann I, Müller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/ STAT pathway. Biochem J 1998;334: 297–314.
   Google Scholar
• Abel J, Spannbrucker N, Fandrey J, Jelkmann W. Serum erythropoietin levels in patients with sepsis and septic shock. Eur J Haematol 1996;57:359–63.
   PubMed Web of Science ®Google Scholar